Catalyst

Slingshot members are tracking this event:

Alexion (ALXN) Presents Top-Line Phase 2/3 PROTECT Data Evaluating Eculizumab (Soliris®) For The Prevention Of Delayed Graft Function (DGF) After Kidney Transplantation

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ALXN

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Top-line Data, Phase 2/3, Protect, Eculizumab, Soliris, Delayed Graft Function, Dgf, Kidney Transplantation